Search > Obesity
156 Participants NeededMy employer runs this trial

ALN-2232 for Obesity

AC
Overseen ByAlnylam Clinical Trial Information Line
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Alnylam Pharmaceuticals
Must not be taking: Weight management, Antidiabetic
Disqualifiers: Clinically significant disease, others

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to:

* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity

* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity

* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

Who Is on the Research Team?

MD

Medical Director

Principal Investigator

Alnylam Pharmaceuticals

Are You a Good Fit for This Trial?

Inclusion Criteria

Has a hemoglobin A1c (HbA1c) <6.5%
My BMI is between 30 and 40.

Exclusion Criteria

I do not have any serious health problems that could affect my safety in this study.
I am currently taking medication for weight management or diabetes.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive single or multiple doses of ALN-2232, with or without tirzepatide

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • ALN-2232

How Is the Trial Designed?

7

Treatment groups

Experimental Treatment

Placebo Group

Group I: Part C: TirzepatideExperimental Treatment1 Intervention
Group II: Part C: ALN-2232Experimental Treatment2 Interventions
Group III: Part B: ALN-2232Experimental Treatment1 Intervention
Group IV: Part A: ALN-2232Experimental Treatment1 Intervention
Group V: Part B: PlaceboPlacebo Group1 Intervention
Group VI: Part A: PlaceboPlacebo Group1 Intervention
Group VII: Part C: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alnylam Pharmaceuticals

Lead Sponsor

Trials
81
Recruited
16,100+

Dr. Yvonne Greenstreet

Alnylam Pharmaceuticals

Chief Executive Officer since 2021

MD from the University of Leeds, MBA from INSEAD

Dr. Pushkal Garg

Alnylam Pharmaceuticals

Chief Medical Officer since 2016

MD from Columbia University

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.